🔗 Permalink

Inventor profile of:

Mark Cobbold

City:

Winchester, Massachusetts

Country:

United States

Published Applications:

Last publication date:

2026-02-05

Top Assignees for applications by Mark Cobbold

The entities that hold a legal rights for patent applications filed by inventor Cobbold Mark:

THE UNIVERSITY OF BIRMINGHAM 11 Birmingham, United Kingdom
The General Hospital Corporation 6 Boston, MA United States
UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2 Charlottesville, VA United States
DNA TWOPOINTO INC. 2 Newark, CA United States
Revitope Limited 1 London, United Kingdom
University of Virginia Patent Foundation 1 Charlottesville, United States
DNA Twopointo 1 Newark, CA United States
Revitope Limited 1 Hertfordshire, United Kingdom

Recent patent applications by Cobbold Mark

Mark Cobbold from Winchester, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-02-05

US20260035416A1

Chemistry; metallurgy

MODIFIED T CELLS AND METHODS OF THEIR USE

#2 | 2023-09-28

US20230302054A1

Human necessities

MODIFICATION OF T CELLS

#3 | 2023-08-10

US20230250150A1

Chemistry; metallurgy

CHIMERIC ANTIGEN RECEPTORS BASED ON ALTERNATIVE SIGNAL 1 DOMAINS

#4 | 2023-01-26

US20230025608A1

Human necessities

Target peptides for immunotherapy and diagnostics

#5 | 2022-10-13

US20220323600A1

Human necessities

TEAC AND ATTAC IMMUNOONCOLOGY COMPOSITIONS AND METHODS

#6 | 2022-08-25

US20220265791A1

Human necessities

TARGET PEPTIDES FOR CANCER THERAPY AND DIAGNOSTICS

#7 | 2022-06-02

US20220170044A1

Chemistry; metallurgy

TRANSPOSON-BASED MODIFICATIONS OF IMMUNE CELLS

#8 | 2021-07-22

US20210220337A1

Human necessities

METHODS OF MODULATING ANTIGENICITY TO ENHANCE RECOGNITION BY T-CELLS

#9 | 2021-05-27

US20210154279A1

Human necessities

TARGET PEPTIDES FOR COLORECTAL CANCER THERAPY AND DIAGNOSTICS

#10 | 2021-05-13

US20210137978A1

Human necessities

MODIFIED T CELLS AND METHODS OF THEIR USE

#11 | 2020-01-16

US20200016262A1

Human necessities

Targeting Moiety Peptide Epitope Complexes Having a Plurality of T-Cell Epitopes

#12 | 2019-12-12

US20190374627A1

Human necessities

TARGET PEPTIDES FOR CANCER THERAPY AND DIAGNOSTICS

#13 | 2019-10-31

US20190330302A1

Chemistry; metallurgy

Chimeric antigen receptors based on alternative signal 1 domains

#14 | 2019-09-05

US20190270779A1

Chemistry; metallurgy

Re-directed immunotherapy

#15 | 2018-12-06

US20180346568A1

Chemistry; metallurgy

Functional Antibody Fragment Complementation for a Two-Components System for Redirected Killing of Unwanted Cells

#16 | 2018-04-19

US20180105599A1

Chemistry; metallurgy

Immunotherapeutic molecules and uses

#17 | 2017-11-23

US20170333541A1

Human necessities

TARGET PEPTIDES FOR IMMUNOTHERAPY AND DIAGNOSTICS

#18 | 2017-06-01

US20170152316A1

Chemistry; metallurgy

Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells

#19 | 2016-08-04

US20160220665A1

Human necessities

Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes

#20 | 2016-07-21

US20160206726A1

Human necessities

IMMUNOTHERAPY

#21 | 2016-04-21

US20160106862A1

Human necessities

Re-directed immunotherapy

#22 | 2016-02-11

US20160039942A1

Chemistry; metallurgy

Immunotherapeutic molecules and uses

InventorID:

1438596 ⎘